Sanofi SNY was a big mover last session, as the company saw its shares rise more than 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $38.02 –$50.54 in the past one-month time frame, witnessed a sharp increase yesterday.
The upmove came following news that the company has treated the first patient outside the United States with Kevzara (sarilumab) hospitalized with severe COVID-19.
The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Sanofi currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Sanofi price | Sanofi Quote
Investors interested in the Large Cap Pharmaceuticals industry may consider Innoviva, Inc. INVA, which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Zacks Top 10 Stocks for 2020
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020?
Last year's 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2020 today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Sanofi (SNY) : Free Stock Analysis Report
Innoviva, Inc. (INVA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research